BRAF and melanoma: For example, a patient with AGK::BRAF-driven melanoma showed resistance to vemurafenib but sensitivity to sorafenib in vitro and subsequently a durable response to sorafenib in vivo32, and a patient with AGK::BRAF-positive myoepithelial carcinoma responded to cobimetinib34.